Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 3
2006 2
2007 3
2008 1
2009 2
2010 6
2011 3
2012 2
2013 2
2014 5
2015 5
2016 7
2017 3
2018 6
2019 1
2020 7
2021 4
2022 5
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, Vilaseca-Jolonch A, Llufriu S, Blanco Y, Hegen H, Berek K, Perez-Miralles F, Rejdak K, Villar LM, Monreal E, Alvarez-Lafuente R, Soylu OK, Abdelhak A, Bachhuber F, Tumani H, Martínez-Yélamos S, Sánchez-López AJ, García-Merino A, Gutiérrez L, Castillo-Trivino T, Lycke J, Rosenstein I, Furlan R, Filippi M, Téllez N, Ramió-Torrentà L, Lünemann JD, Wiendl H, Eichau S, Khalil M, Kuhle J, Montalban X, Comabella M. Fissolo N, et al. Among authors: martinez yelamos s. J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):410-418. doi: 10.1136/jnnp-2023-332251. J Neurol Neurosurg Psychiatry. 2024. PMID: 37940409
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
Muñoz-Vendrell A, Arroyo-Pereiro P, León I, Bau L, Matas E, Martínez-Yélamos A, Martínez-Yélamos S, Romero-Pinel L. Muñoz-Vendrell A, et al. Among authors: martinez yelamos s. J Neurol. 2023 May;270(5):2559-2566. doi: 10.1007/s00415-023-11645-x. Epub 2023 Mar 13. J Neurol. 2023. PMID: 36913038 Free PMC article. Clinical Trial.
[Gardener pupil].
Jaraba Armas S, Lara Rodríguez B, Labori Trias M, Martínez-Yélamos S. Jaraba Armas S, et al. Among authors: martinez yelamos s. Med Clin (Barc). 2012 Jul 7;139(4):182. doi: 10.1016/j.medcli.2012.01.011. Epub 2012 Mar 6. Med Clin (Barc). 2012. PMID: 22397980 Spanish. No abstract available.
Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis.
Lleixà C, Caballero-Ávila M, Pascual-Goñi E, Martín-Aguilar L, Vidal N, Tejada C, Valdés-Hevia E, Zárate E, Vesperinas A, Collet R, Franco-Leyva T, Martínez-Martínez L, Moga E, Cortés-Vicente E, Rojas-García R, Gómez-Anson B, Gil A, González-Mingot C, Brieva L, Martínez-Yélamos S, Querol L. Lleixà C, et al. Among authors: martinez yelamos s. Brain Commun. 2023 Apr 4;5(2):fcad109. doi: 10.1093/braincomms/fcad109. eCollection 2023. Brain Commun. 2023. PMID: 37091585 Free PMC article.
[Biomarkers in multiple sclerosis].
Fernández Ó, Arroyo-González R, Rodríguez-Antigüedad A, García-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, Meca-Lallana JE, Prieto JM, Ramió-Torrentà L, Martínez-Yélamos S, Montalban X. Fernández Ó, et al. Among authors: martinez yelamos s. Rev Neurol. 2013 Apr 1;56(7):375-90. Rev Neurol. 2013. PMID: 23520007 Free article. Review. Spanish.
72 results